title: Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy.
abstract: We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade. In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT). The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection. The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head. A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy. The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter. External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter. Eleven years have now passed since the laparotomy, and the patient continues to lead a normal daily life working as a banker. The cumulative dose of UFT has reached 2511 g without any significant adverse effects. This case suggests that oral UFT might suppress the progression of ICC, contributing to this patient's 11-year survival period.
authors.affiliation: Department of Surgery, Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Graduate School of Medicine, University of Tokyo, Japan. takemuranobu-tky@umin.ac.jp
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Takemura
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kokudo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takazawa
authors.forename: Keiji
authors.initials: K
authors.lastname: Sano
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Kuni
authors.initials: K
authors.lastname: Ohtomo
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Makuuchi
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000532:radiotherapy; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D008297:Male; D011879:Radiotherapy Dosage; D017741:Survivors; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur